Sign Up Today and Learn More About Nimbus Therapeutics Stock
Invest in or calculate the value of your shares in Nimbus Therapeutics or other pre-IPO companies through EquityZen's platform.
Nimbus Therapeutics Stock
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
About Nimbus Therapeutics Stock
Founded
2009
Headquarters
Cambridge, MA, US
Total Funding
137M
Industries
Software, Artificial Intelligence, Data and Analytics
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Nimbus Therapeutics Press Mentions
Stay in the know about the latest news on Nimbus Therapeutics
Nimbus Nabs $65M to Advance In-House Drug Discoveries to the Clinic
Xconomy • Jun 05, 2018
Nimbus Therapeutics Picks Up Additional $65 Million
Wall Streets Journal • Jun 05, 2018
Nimbus Therapeutics Announces Departure of Chief Scientific Officer Rosana Kapeller, M.D., Ph.D.
• Mar 08, 2018
Nimbus Therapeutics Management
Leadership team at Nimbus Therapeutics
Chief Business Officer
Jeb Keiper
Head of Chemistry
Ronald Wester
Join now and verify your accreditation status to gain access to:
- Nimbus Therapeutics current valuation
- Nimbus Therapeutics stock price
- Available deals in Nimbus Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Nimbus Therapeutics Stock
How to invest in Nimbus Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Nimbus Therapeutics through EquityZen funds. These investments are made available by existing Nimbus Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Nimbus Therapeutics stock?
Shareholders can sell their Nimbus Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
